Evidence map›Paper›PMID 39598399›Full record

ArticlePharmaceuticals (Basel, Switzerland)2024

In Silico and In Vitro Investigation of Cytotoxicity and Apoptosis of Acridine/Sulfonamide Hybrids Targeting Topoisomerases I and II.

Mohamed Badr, Elshaymaa I Elmongy, Doaa Elkhateeb, Yasmine S Moemen, Ashraf Khalil, Hadeer Ali, Reem Binsuwaidan, Feby Awadallah, Ibrahim El Tantawy El Sayed

Abstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mohamed BadrDepartment of Biochemistry, Faculty of Pharmacy, Menoufia University, Shebin El-Kom 6131567, Egypt.
Elshaymaa I ElmongyDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Helwan University, Ain Helwan, Cairo P.O. Box 11795, Egypt.ORCID 0000-0003-1160-5040
Doaa ElkhateebChemistry Department, Faculty of Science, Menoufia University, Shebin El-Kom 32511, Egypt.
Yasmine S MoemenClinical Pathology Department, National Liver Institute, Menoufia University, Shebin El-Kom 32511, Egypt.
Ashraf KhalilDepartment of Clinical Biochemistry and Molecular Diagnostics, National Liver Institute, Menoufia University, Shebin El-Kom 32511, Egypt.
Hadeer AliChemistry Department, Faculty of Science, Menoufia University, Shebin El-Kom 32511, Egypt.
Reem BinsuwaidanDepartment of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia.ORCID 0000-0003-1406-282X
Feby AwadallahChemistry Department, Faculty of Science, Menoufia University, Shebin El-Kom 32511, Egypt.
Ibrahim El Tantawy El SayedChemistry Department, Faculty of Science, Menoufia University, Shebin El-Kom 32511, Egypt.ORCID 0000-0003-1227-7931

Funding

Princess Nourah bint Abdulrahman University Researchers Supporting Project,‎ PNURSP2024R304
6 · The paper itself

Abstract

backgroundSulfonamide acridine derivatives have garnered significant attention from medicinal chemists due to their diverse range of biological activities.

methodsIn this study, eleven compounds were synthesized according to the literature, and their impact on cell growth inhibition, induction of apoptosis, and cell cycle distribution were assessed in three different cell lines. Their inhibitory effects on the topoisomerase (Topo) I and II were investigated in vitro. Molecular docking studies were conducted to predict the binding affinities of these compounds for crystallized downloaded topoisomerases.

resultsThe compounds were examined in vitro for their anticancer activity against human hepatic (HepG2) colon (HCT-8) and breast (MCF-7) carcinoma cell lines. Compound

conclusionCompounds

Indexed as

acridinescytotoxicitymolecular dockingtopoisomerase

Identifiers

PMID39598399
PMCPMC11597879

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.